Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
15 mai 2023 16h47 HE | Adamis Pharmaceuticals Corporation
SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company focused on developing and commercializing products in...
22157.jpg
Insights on the Naloxone Global Market to 2030 - Increasing Prevalence of Opioid Overdoses Remains as The Most Impactful Driver
30 janv. 2023 09h33 HE | Research and Markets
Dublin, Jan. 30, 2023 (GLOBE NEWSWIRE) -- The "Naloxone Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to...
IMG_0462.JPG
Heart to Heart CPR Raises Awareness of Ontario's NEW Workplace Naloxone Requirements Effective June 1, 2023
10 janv. 2023 08h08 HE | Heart to Heart First Aid CPR Services Inc
TORONTO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- As of June 1, 2023, the Occupational Health and Safety Act (OHSA) will require workplaces to have a naloxone kit if an employer becomes aware, or ought...
Stop Opioid Overdoes Naloxone
Fentanyl Drives Fatal Overdoses to Over 107,000 Annually in the U.S. - Healthcare Providers' Effort to Fight Back
24 août 2022 09h00 HE | Cordant Health Solutions
PORTLAND, Ore., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Cordant Health Solutions®, a leader in providing innovative tools for addiction treatment programs, is partnering with addiction treatment providers...
ZIMHI Device.png
US WorldMeds Launches ZIMHIDirect.com
05 juil. 2022 11h32 HE | US WorldMeds
LOUISVILLE, Ky., July 05, 2022 (GLOBE NEWSWIRE) -- USWM, LLC (US WorldMeds) announces ZIMHI™ (naloxone HCL Injection) 5mg/0.5mL is now available for ordering by public interest groups through the...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
01 juin 2022 08h00 HE | Adamis Pharmaceuticals Corporation
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Global Suboxone Market
Global Global Suboxone Market Analysis/Forecast Report 2022-2030: Increasing Product Launches is Expected to Drive Growth
24 mai 2022 06h49 HE | Research and Markets
Dublin, May 24, 2022 (GLOBE NEWSWIRE) -- The "Global Suboxone Market by Type, Formulation, Distribution Channel, and Region - Size, Share, Outlook, and Opportunity Analysis, 2022-2030" report has...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™
01 déc. 2021 07h30 HE | Adamis Pharmaceuticals Corporation
SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of...
Adamis Pharmaceuticals logo
Adamis Receives FDA Approval for ZIMHI
18 oct. 2021 07h30 HE | Adamis Pharmaceuticals Corporation
SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone...
Adamis Pharmaceuticals logo
Adamis Provides Update on ZIMHI™
09 juin 2021 07h30 HE | Adamis Pharmaceuticals Corporation
SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s...